The use of antibiotic prophylaxis in patients with solid tumours — when and to whom? by Kardas, Joanna & Buraczewska, Agnieszka
128
REVIEW ARTICLE
Address for correspondence:
Lek. Joanna Kardas
Klinika Onkologii, 
Wojskowy Instytut Medyczny 
ul. Szaserów 128, 04–141 Warszawa
e-mail: jkardas@wim.mil.pl
Joanna Kardas, Agnieszka Buraczewska
Oncology Clinic, Military Institute of Medicine, Warsaw
The use of antibiotic prophylaxis  
in patients with solid tumours  
— when and to whom?
ABSTRACT
Cancer patients treated due to solid tumours are exposed to bacterial, fungal, and viral infections, and the high 
morbidity connected to them is caused by cancer itself and anticancer therapy. Systemic chemotherapy and 
local treatment, e.g. surgery and/or radiotherapy, can contribute to infectious complication, which have a negative 
impact on the efficacy of the treatment and patients’ quality of life. Therefore, there is a need to look for prevention 
methods, and antibiotics might be one of the options. Since granulocyte colony stimulating factors (G-CSF) ap-
peared, the use of antibiotic prophylaxis was limited to a few indications. In patients with afebrile neutropaenia the 
use of antimicrobial therapy should be considered only when coexisting risk factors exist. There are also certain 
situations in cancer therapy when antibiotic prophylaxis could be useful. The presented publication is aimed to 
identify situations when the treating clinician should consider antibiotic prophylaxis in a patient with a solid tumour.
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Introduction
Cancer patients are exposed to infectious complica-
tions due to underlying malignancy, concomitant dis-
eases, as well as anticancer treatment. Therapeutic mo-
dalities, supportive care, and prophylactic methods are 
determined by cancer type and also its location and stage 
at diagnosis. There are significant differences among 
treatment complications between elderly patients with 
internal concomitant diseases and lower performance 
status and young patients, who generally do well despite 
even more advanced cancer. Finally, some diagnostic 
and treatment procedures imply specific prophylactic 
methods, which aim to limit infectious diseases, improve 
quality of life, and optimise anticancer treatment. It 
should be also underlined that prophylactic antibiotic 
therapy should be employed when the expected benefits 
outweigh the possible risks of side effects like allergic 
reactions, Clostridium difficile infection, or resistant 
strains selection.
The following sections present the situations in which 
health care professionals should consider prophylactic 
antibiotic therapy as well as when this is not recom-
mended.
General recommendations
The sensitivity of solid tumours to chemotherapy 
varies greatly. Cytotoxic drugs affect not only cancer 
cells but also normal human tissues. Fast growing cells, 
like mouth and gastrointestinal (GI) tract mucosa or 
haematopoietic cells, are especially susceptible. Time 
to mucosa or bone marrow toxicity usually ranges 
from 7 to 14 days, but it depends on the normal cell 
mitosis rate in these organs as well as on the type and 
dose of chemotherapy. Simultaneous damage of GI 
mucosa and/or bone marrow suppression contributes 
to infectious complications. The use of G-CSF is an 
acknowledged method of prevention of infectious com-
plications of expected neutropaenia in patients after 
chemotherapy. Primary G-CSF prophylaxis beneficially 
influences the prevalence and duration of febrile neut-
ropaenia, risk of bacterial infections, antibiotic therapy 
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duration, and number of days with hospitalisation. 
However, the impact of this method on decreased risk 
of death has not been confirmed yet [1]. The decision 
regarding introducing of G-CSF is mainly — but not 
entirely — based on the type of cancer and its chemo-
therapy. Primary prophylaxis of febrile neutropaenia 
with G-CSF is justified when chemotherapy with high 
risk index of febrile neutropaenia (> 20%) is used. 
In patients treated with chemotherapy of moderate 
risk of febrile neutropaenia (10–20%) the reasons for 
G-CSF introduction include the presence of additional 
risk factors and the occurrence of febrile neutropaenia 
complications (age > 65 years, higher stages of cancer, 
metastases to bone marrow, low performance status, 
previous radiotherapy on large area of bone marrow, 
malnutrition, female gender, anaemia, and kidney and 
liver impairment). Secondary prophylaxis with G-CSF 
should be considered in radically treated patients [2].
The use of antibiotics in primary prophylaxis of 
infectious complications is much more complicated. 
A meta-analysis of over 100 clinical trials, including 
13,000 patients, published in 2012 showed significant 
benefits in terms of decreased mortality (of any causes) 
after prophylactic antibiotic therapy in patients during 
chemotherapy with neutropaenia but without febrile 
neutropaenia as compared to placebo or no prophylax-
is. Additionally, it was noted that patients who under-
went prophylaxis have decreased risk of death due to 
infection, risk of febrile occurrence, infection (clinically 
overt or microbiologically confirmed), and bacteraemia. 
The benefits outweighed potential risks of adverse 
events or inducing of drug-resistance. This treatment 
included: quinolones, trimethoprim-sulfamethoxazole 
(co-trimoxazole), systemic antibiotics (cephalosporins, 
vancomycin), and antibiotics unabsorbed from the GI 
tract (polymyxin, colistin, and neomycin). However, 
the majority of patients included to this meta-analysis 
were diagnosed with haematological malignancies [3]. 
A British study published in 2005, in which over 1500 pa-
tients received prophylaxis with either levofloxacin or 
placebo (nearly 90% of included patients had solid 
tumours), indicated decreased risk of febrile infection 
and hospitalisation in patients in the prophylactic group. 
The majority of patients received chemotherapy of low 
or moderate risk of febrile neutropenia. There were no 
differences between groups regarding mortality due to 
infection [4]. As patients with solid tumours treated with 
standard chemotherapy are usually put at low general 
risk of infection (neutropenia duration < 7 days), Amer-
ican recommendations do not qualify those patients for 
use of antibiotic in prophylaxis of bacterial infections 
[5]. However, use of additional antibacterial prevention 
is justified in selected patients with neutropaenia in 
order to decrease the prevalence of serious infectious 
complications, delay the occurrence of infection, as 
well as decrease a hospitalisation rate. The group at 
high risk of infectious complications includes patients 
with expected time of Grade 4 neutropaenia according 
to CTCAE (common terminology criteria for adverse 
events) exceeding 7–10 days. As a result, the final de-
cision regarding introduction of prophylactic antibiotic 
therapy is influenced by the type of chemotherapy, type 
of cancer and its stage, as well as previous episodes of 
febrile neutropaenia. Additional factors indicating the 
need for prophylactic use of antibiotics include: older 
patient’s age, concomitant diabetes, chronic lung dis-
ease, interrupted continuity of skin or mucosa, expected 
inflammation of mucosa after chemotherapy, and body 
overloading with iron [6]. Fluoroquinolones (ciproflox-
acin and levofloxacin) are the most commonly used 
antibiotics in antibacterial prophylaxis. It was shown that 
the use of fluoroquinolones decreases the prevalence of 
febrile neutropaenia and infections microbiologically 
confirmed as compared to placebo or no prophylaxis 
[3, 4]. Additionally, these antibiotics less frequently 
induce resistant strains as compared to co-trimoxazole, 
fewer adverse events, and also adverse events leading to 
discontinuation of the treatment [3]. Fluoroquinolones 
could be used in antibacterial prophylaxis in patients 
with high risk of febrile neutropaenia after exclusion 
of local bacterial resistance to this group of antibio - 
tics. Ciprofloxacin is administered in the dose 2 × 500 mg 
daily, and levofloxacin in the dose 1 × 500 mg daily. 
Levofloxacin shows lower efficacy against Pseudomonas 
aeruginosa as compared to ciprofloxacin but is more 
active against Gram-positive strains, e.g. Streptococ-
cus. It is not recommended to add to prophylaxis with 
fluoroquinolones another antibiotic, more active against 
Gram-positive bacteria, because this does not decrease 
the risk of death due to infection but increases the risk 
of GI complications and infections elicited by resistant 
strains. There is no specific recommendation regarding 
duration of antibiotic prophylaxis, which is usually intro-
duced on the first day of chemotherapy or the day after 
its cessation, and the therapy is continued until yielding 
the risk of neutropaenia or until start of treatment with 
broad-spectrum antibiotics in patients with fever [7].
Some chemotherapy protocols include distinct rec-
ommendations regarding prophylactic antibiotic thera-
py, different than general, which result from the design 
of pivotal study being a base of introducing this therapy 
to clinical practice. For example, it is not recommend-
ed to use G-CSF during induction chemotherapy TPF 
(docetaxel, cisplatin, fluorouracil), which is indicated in 
patients with head and neck cancer (with a risk of febrile 
neutropaenia of 5–15%); however, all patients receiving 
TPF protocol in the clinical study received ciprofloxacin 
between cycle days 5 and 15) [8, 9].
Indications to use antibiotics and growth factors 
should be considered separately. It has not been investi-
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gated in prospective clinical trials so far, which method is 
more efficient as well as the value of their simultaneous 
use was also not established. A report was published 
in 2015 [10], retrospectively analysing the prevalence 
of febrile neutropaenia in 340 breast cancer patients 
undergoing adjuvant chemotherapy TC (docetaxel, 
cyclophosphamide) and additionally receiving different 
methods of primary prophylaxis, e.g. G-CSF, antibiotic, 
or no prophylaxis. Febrile neutropaenia was diagnosed 
in 1%, 11%, and 32% of patients, respectively. The risk 
of this complication during chemotherapy according 
TC protocol exceeds 30%, so this amplified the recom-
mendations to use G-CSF prophylactically, despite the 
low rate of febrile neutropaenia in a previous phase III 
clinical study. Nevertheless, antibiotic could be used if 
the patient does not tolerate growth factors or denies 
their taking. 
Prophylaxis of pulmonary pneumocystis
Pulmonary pneumocystis is an opportunistic infec-
tion caused by fungus Pneumocystis jiroveci. More than 
half of the population are carriers of this microorgan-
ism. Immunocompetent individuals have no signs and 
symptoms but they can be a source of infection for 
susceptible patients. In immunocompromised patients, 
infection could cause severe respiratory distress, quite 
often leading to death. Among patients treated for sol-
id tumours the most exposed to this infection are the 
patients persistently treated with corticosteroids and 
patients with gliomas, who have undergone adjuvant 
radiochemotherapy with temozolomide. American 
societies [11] recommend consideration of prophylaxis 
with co-trimoxazole in patients at risk of this complica-
tion, e.g. in patients treated with steroids in a dose of at 
least 20 mg prednisone (or 3 mg dexamethasone) daily 
for four weeks or longer. The prevalence of pulmonary 
pneumocystis in patients with gliomas accounts for ap-
proximately 1%, with mortality exceeding 50% [12]. In 
the study of Stupp et al. [13] this rate was even higher 
and was 3% (prophylaxis with pentamidine became 
mandatory after pulmonary pneumocystis diagnosed in 
the first two patients among the 15 included in the trial).
Other opportunistic infections observed in this group 
of patients include fungal infections, as well as cyto-
megalovirus, herpes zoster virus, herpes simplex virus, 
and hepatitis B virus infections. Temozolomide induces 
delayed myelosuppression, with its nadir at 5–6 weeks of 
treatment. The risk of opportunistic infections increas-
es when CD4+ cell count drops below 200/µl or total 
lymphocyte count is lower than 500/µl. 
Dutch researchers analysed available literature 
regarding indications to prophylactic antibiotic thera-
py in patients treated due to gliomas [12]. Pulmonary 
pneumocystis prevention is recommended when corti-
costeroids are administered in a daily equivalent dose 
of at least 3 mg of dexamethasone during more than 
three weeks and should be continued for one month 
after cessation of steroid therapy providing normalised 
CD4+ cells or lymphocyte count. Additionally, this 
kind of prophylaxis should be considered in the follow-
ing situations:
 — in elderly patients (> 65 years old) with pulmonary 
disease — prophylaxis should be stopped only when 
normal CD4+ cells and lymphocyte counts recover;
 — in patients during immunosuppressive treatment 
after organ or bone marrow transplantation, with 
rheumatic diseases, connective tissue disease, or 
inflammatory bowel disease;
 — in HIV-positive patients with CD4+ cell count below 
200/µl at start of treatment;
 — in patients with pulmonary pneumocystis or common 
opportunistic infections in their medical history.
Concluding: prophylaxis of pulmonary pneumocystis 
should be initiated in patients with lymphocyte count 
below 500/µl (or CD4+ cell count below 200/µl). This 
preventive treatment should be continued until normali-
sation of haematological parameters. The drug of choice 
is oral co-trimoxazole in the dose of 480 mg once daily or 
960 mg three times a week. In the case of co-trimoxazole 
intolerance, pentamidine inhalations should be used 
(300 mg once every four weeks), dapson 100 mg once 
daily orally, or atovaquone 1500 mg daily orally [12].
Prophylaxis of skin complications 
during anti-EGFR therapy
The innovative therapies are connected with the 
new sort of treatment-related adverse event, which 
have not been observed during standard chemotherapy. 
Epidermal growth factor receptor (EGFR) is one of the 
molecular targets for new drugs used in oncology. EGFR 
plays a significant role in the development of non-small 
cell lung cancer (NSCLC), squamous cell head and neck 
cancer, colon cancer, and breast cancer. EGFR recep-
tor is a member of the human epidermal growth factor 
(HER) family, containing four membrane glycoprotein 
receptors. EGFR protein could be indicated in the ma-
jority of tissues, including blood, the immune system, as 
well as nervous, musculoskeletal, digestive, respiratory, 
endocrine, and reproductive systems. EGFR expresses 
in keratinocytes, eccrine sweat glands and sebaceous 
glands, hair sheath, and vascular endothelial cells. Active 
receptor transmits a signal to intracellular space, which 
leads to a biological reaction, resulting in regulation of 
many processes, including proliferation, differentiation, 
cell cycle, migration, and cell survival [14]. There are 
two types of EGFR inhibitors: low-molecular tyrosine 
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kinase inhibitors (TKIs), competitively blocking of 
phosphorylation receptors, and monoclonal antibodies 
(mAbs) binding to extracellular receptor domains. An-
ti-EGFR monoclonal antibodies, like panitumumab and 
cetuximab are used in patients with metastatic colon 
cancer meeting molecular criteria (wild — type KRAS 
and NRAS genes in tumour cells). Low-molecular EGFR 
TKIs (erlotinib, gefitinib, afatinib) are used in patients 
with NSCLC with predominant adenocarcinoma histol-
ogy and meeting specific molecular criteria (activating 
EGFR gene mutations in tumour cells). 
Targeted and conventional therapies differ not only 
in terms of efficacy measures, but they also show distinct 
adverse event profiles. The most common complications 
during chemotherapy include haematological and gener-
al effects, and targeted therapy is characterised mainly 
by skin and mucosal changes.
EGFR inhibitors imbalance the proliferation and 
differentiation of keratinocytes. It could cause direct 
immune reaction and produce an inflammatory reaction 
with T-cell infiltration of hair follicles. Finally, it could 
subsequently result in rupture of the hair system with the 
influence of neutrophils and damage of sweat glands [15, 
16]. Papulopustular rash is observed in more than 90% 
of patients treated with anti-EGFR antibodies, definitely 
limiting their quality of life [17]. Usually it occurs be-
tween 8 and 10 days after introducing of therapy. There 
are five grades of skin toxicity (CTCAE) depending on 
the intensity of symptoms [18]:
 — 1 grade: papulopustular rash involving < 10% of 
body surface area ± pruritus and paraesthesia;
 — 2 grade: symptoms as mentioned above and addi-
tionally papules and pustules covering 10–30% of 
body surface area;
 — 3 grade: symptoms as mentioned above and addition-
ally papules and pustules covering > 30% of body 
surface area, local inflammation — oral antibiotics 
are indicated;
 — 4 grade: papules and pustules covering some body 
surface area without assessing the percentage, when 
accompanied by expansive, life-threatening inflam-
mation demanding intravenous antibiotic use;
 — 5 grade: death.
As compared to mAbs, the reaction after TKIs is 
less intensive. Grade 3 or 4 papulopustular rash is less 
common and occurs in up to 9% of patients [19, 20]. 
Skin changes, usually located on the face and upper 
trunk, definitely limit the patient’s quality of life, and 
sometimes require modification or even discontinuation 
of the treatment. 
As it has been proven so far that occurrence of 
skin toxicity during anti-EGFR therapy positively cor-
relates with anticancer response, proper treatment of 
this complication is one the most important parts of 
management [21].
The management of skin changes depends on their 
intensity [22, 23]. In patients with grade 1 and 2 skin tox-
icities care preparations are used — moisturising creams 
containing urea, soft cleaning preparations, emollients, 
local antibiotics (clindamycin, erythromycin gel), local 
glucocorticosteroids, and oral antihistamines. In higher 
grades oral antibiotics (from the tetracycline group or 
others in cases of supra-infection of Staphylococcus au-
reus — honey-coloured scabs) and oral corticosteroids 
are additionally used. Despite this some patients need 
dose reduction of anti-EGFR treatment, postponement 
of the next dose, or even treatment discontinuation. 
Because of skin toxicity limiting efficient anticancer 
treatment currently there is a tendency to earlier in-
troducing of skin changes therapy, e.g. oral antibiotics 
are more often used after the occurrence of first papu-
lopustular lesions. 
There are some observations supporting use of 
primary antibiotic prophylaxis in patients receiving 
anti-EGFR treatment. The phase II study STEPP in 
patients treated with panitumumab assessed the effect 
of primary prophylaxis with doxycycline 2 × 100 mg for 
six weeks on skin toxicity and quality of life compared 
to reactive treatment (doxycycline administration only 
after occurrence of skin changes). It was shown that 
skin toxicity of grade 2 or higher was 50% less frequent 
in patients receiving prophylaxis, and quality of life 
was also better in this group as compared to reactively 
treated patients [24]. 
In 2013 an Italian study was published in which 
lung cancer patients treated with erlotinib and colon 
cancer patients treated with cetuximab or panitumumab 
received prophylactically lymecycline in the dose of 
300 mg daily. During the first three months of therapy 
grade 2 adverse reactions in the skin occurred in 27% 
of patients. A decreasing prevalence of serious skin 
toxicities with higher percentage of grade 1 changes 
was also indicated, without need for anti-EGFR dose 
reduction. Patients’ quality of life was unchanged during 
the whole study [25].
Another Japanese study retrospectively analyzed 
55 panitumumab-treated colon cancer patients. One 
group of patients received minocycline as a prophylaxis 
of skin changes and the rest was treated with minocycline 
only after occurrence of complications. Significantly less 
frequent complications were observed in group receiving 
primary prophylaxis, without any impact on efficacy of 
anti-EGFR therapy [26].
Use of tetracycline (2 × 250 mg for four weeks) in 
primary prophylaxis of skin toxicity was investigated 
in NSCLC patients treated with afatinib [27]. In total 
90 patients were assigned to the group receiving tetra-
cycline prophylactically and treated with antibiotic after 
occurrence of grade 3 or 4 toxicity. The frequency and 
intensity of skin complications during afatinib treat-
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ment decreased by more than 60% and tetracycline was 
well tolerated.
The question arose, if acneiform rash is predictive 
factor of response to anti-EGFR treatment, could the 
use of tetracycline decreas treatment efficacy? Canadian 
researchers tried to address such a question [28] and ret-
rospectively analysed 119 patients with advanced colon 
cancer treated with panitumumab or cetuximab. One 
group of patients received oral antibiotics in prophylaxis 
and the other after occurrence of rash. There was no 
difference between groups according to treatment ef-
ficacy, e.g. in both groups overall survival time and the 
number of anti-EGFR treatment cycles were similar.
Therefore, primary antibiotic prophylaxis in patients 
receiving anti-EGFR therapy decreases the frequency 
of higher grade skin toxicities and improves quality of 
life as compared to patients treated with antibiotics only 
after the occurrence of toxic signs. The MASCC Skin 
Toxicity Study Group recommends use of tetracyclines 
in prophylaxis, e.g. doxycycline in the dose of 100 mg 
twice daily for the first six weeks, and minocycline 
100 mg daily for eight weeks. Doxycycline has a better 
safety profile, especially in patients with impaired kidney 
functions, whilst minocycline is less photosensitising 
(recommendation level IIa) [29].
Prophylaxis of urinary tract infections
Urinary tract infection is a common problem in 
patients treated due to solid tumours; however, there 
are no data regarding specific prophylaxis in this group 
of patients. Additionally, management of asymptomatic 
bacteriuria in these patients is also a very interesting 
topic. Prophylaxis is not recommended in otherwise 
healthy individuals (except pregnant women). Antibiotic 
prophylaxis is also not recommended for prevention of 
urinary tract infections in patients with non-infiltrating 
bladder cancer with asymptomatic bacteriuria and 
requirement of BCG therapy [30, 31]. The following 
section presents Polish recommendations regarding 
prophylaxis of urinary tract infection in the general 
population. It seems that patients treated due to solid 
tumours need individualised decisions regarding prophy-
laxis of urinary tract infection.
In patients with chronic urethral catheterisation 
routine antibiotic prophylaxis of urinary tract infection 
is not recommended. Female patients with recurrent 
non-complicated urinary tract infections in medical 
history (at least three episodes during year or at least 
two episodes during six months) benefit from antibiotic 
prophylaxis in terms of decreasing the number of urinary 
tract infection episodes, but with more frequent adverse 
events (vaginal and oral fungal infections, rash, nausea). 
Antibiotic treatment usually lasts 6–12 months. Ad-
ministered drugs included: co-trimoxazole (240 mg 
daily or three times a week), trimethoprim 100 mg 
daily, ciprofloxacin 125 mg daily, cephalexin 250 mg 
daily, cefaclor 250 mg daily, nitrofurantoin 50–100 mg 
daily, norfloxacin 50–100 mg daily, fosfomycin 3 g every 
10 days. However, the number of infections before and 
after initiating prophylaxis is often similar [32]. 
Numerous studies and meta-analyses did not confirm 
the efficacy of cranberry extract [33, 34]. 
Perioperative prophylaxis
Antibiotic prophylaxis is recommended during 
selected surgical operations, when the risk of surgical 
site contamination is high, e.g. operations in clean-con-
taminated surgical site (controlled opening of urinary, 
respiratory, or gastrointestinal tract without clear con-
tamination with its content) or contaminated/soiled 
surgical site (operations with infringement of aseptic 
rules, chronic wound treated by transplantation, pre-
operative perforation of GI, biliary or respiratory tract) 
[35]. Prophylaxis is also recommended in all patients 
undergoing surgical operation, when the infection risk 
could be connected with serious disease or increasing 
mortality, e.g. during profound neutropaenia. The ap-
propriate choice of antibiotic depends on the infection 
risk and possible aetiology of surgical site infection. It 
is said that antibiotic should be administered no earlier 
than two hours before operation (the most optimal 
timing is as short before operation as possible), and 
the subsequent doses are given depending on duration 
of procedure and lost blood volume. Total duration 
of prophylactic antibiotic treatment is limited to 24 or 
48 hours (in the majority of cases the antibiotic is ad-
ministered once) [36].
In thoracosurgical oncology operations (lung resec-
tion, lobectomy, thoracotomy) antibiotic prophylaxis 
is routinely used in all patients (cefazolin, cefuroxime, 
amoxicillin/clavulanic acid, and ampicillin/sulbactam). 
Typical infections include surgical site infections, tra-
cheobronchitis, pneumonia (more frequent in pathogen 
carriers with concomitant chronic obstructive pulmonary 
disease), and lung abscess. The highest risk of postopera-
tive pneumonia is during the first days after operation 
and during hospitalisation in the intensive care unit. 
Patients undergoing oncology surgery of the GI tract 
are exposed to streptococcal infections as well as those 
caused by mouth anaerobes and Gram-negative bacilli, 
mainly E. coli in patients after operations of the upper 
GI tract and small intestine. In such cases antibiotics 
used in prophylaxis include cefazolin or alternatively 
amoxicillin/clavulanic acid, and in patients sensitive to 
beta-lactams — clindamycin or vancomycin in combina-
tion with aminoglycosides or fluoroquinolone. Potential 
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aetiological factors of infections in patients after large 
intestine operations include Gram-negative Enterobac-
teriaceae and anaerobes Bacteroides and Clostridium. 
The antibiotics used in these cases include cefazolin 
with metronidazole, ampicillin/sulbactam, ertapenem, 
and in patients allergic to beta-lactams — clindamycin 
(or metronidazole in combination with aminoglycosides 
or fluoroquinolone). During operations on the biliary 
tract (Enterobacteriaceae, enterococci, anaerobes) 
ampicillin/sulbactam or ceftriaxone are recommended, 
and in patients allergic to beta-lactams antibiotics as 
presented above. During gynaecological operations with 
abdominal or vaginal hysterectomy it is recommended 
to administer cefazolin (± metronidazole), ampicil-
lin/sulbactam, or amoxicillin/clavulanic acid. 
The risk of bacteraemia in patients undergoing 
urological operations with mucosal bleeding and with 
preoperative bacteriuria is significant, so the European 
Association of Urology (EAU) clearly recommends 
urine culture, the result of which implicates the choice 
of perioperative prophylaxis and its duration. The 
American Urological Association (AUA) recommends 
treatment of bacteriuria or decreasing of bacterial titre 
before operation and prolongation of treatment with 
antibiotics up to 24 hours after surgery [32]. In patients 
undergoing transrectal prostate biopsy or transurethral 
resection of the prostate (TURP) fluoroquinolone or 
co-trimoxazole are given, alternatively aminoglycoside 
(± clindamycin) [37, 38].
In patients undergoing head and neck cancer surgery 
perioperative administration of antibiotic in prophylaxis 
of infectious complications should be considered — clin-
damycin in combination with gentamycin single dose or 
amoxicillin/clavulanic acid or cefuroxime in combination 
with metronidazole [36, 39, 40]. 
Antibiotic prophylaxis is also recommended in pa-
tients undergoing oncology surgery due to breast cancer 
(single dose of cefazolin) [41]. 
Prophylaxis of skin and subcutaneous 
tissue infections
Routine prophylaxis with antibiotics is not recom-
mended in patients with chronic skin changes like 
ulcerations, bedsores, and diabetic foot [42]. Antibiotic 
treatment in this group of patients is indicated in cases 
of general symptoms, broadening of infection to healthy 
tissues, like bones, muscles or fasciae, and should cover 
mainly Gram-positive cocci. The specific group of pa-
tients covers the patients with neutropaenia and chronic 
skin changes — in this case the antibiotic prophylaxis 
should be considered together with an assessment of 
additional risk factors of infectious complications (this 
was presented in previous parts).
Prophylaxis of infections in patients 
with ascites/hepatic encephalopathy 
Patients with malignant ascites or those caused by 
secondary liver failure are usually during end-stage can-
cer. In these cases the management is either supportive 
or to improve quality of life. The use of antibiotics in 
prophylaxis should be limited to selected patients. In 
patients with ascites secondary to liver failure with 
concomitant bleeding prophylactic treatment with 
antibiotics (ceftriaxone 1 × 1 g daily for seven days, 
alternatively norfloxacin 2 × 400 mg) decreases the risk 
of bacterial complications as well as the mortality rate 
[43]. In patients with ascites caused by liver cirrhosis 
with low total protein concentration in peritoneal fluid 
(below 15 g/l) administration of norfloxacin (1 × 400 mg 
daily) could be considered because it reduces the risk of 
spontaneous peritonitis [44, 45]. 
Therapeutic and prophylactic management in pa-
tients with hepatic encephalopathy aims to decrease 
ammonia serum concentration indirectly by decontami-
nation of the GI tract. In order to achieve this, lactulose 
(120–240 ml daily in 3–4 doses) or rifaximin (400 mg 
3 times daily), unabsorbed from GI tract antibiotics 
from the rifamycine group, are administered. Both drugs 
are effective, but rifaximin gives fewer adverse events 
although it is the more expensive option [46–48].
Summary
The use of antibiotics in antibacterial prophylaxis in 
patients with solid tumours is justified only in specific 
situations. Fluoroquinolone prophylaxis should be con-
sidered in patients with the risk of long-term grade IV 
neutropaenia, in patients with additional risk factors, 
and in patients treated with specific chemotherapy 
protocols. Co-trimoxazole is effective in prophylaxis 
of pulmonary pneumocystis in patients with gliomas 
undergoing radiochemotherapy with temozolomide 
and in patients chronically treated with corticosteroids, 
and using of co-trimoxazole is recommended especially 
in cases of concomitant lymphocytopaenia. Antibiotics 
from the tetracycline group are used in prophylaxis of 
skin complications in patients receiving anti-EGFR 
treatment, because they decrease the frequency of those 
complications and improve quality of life as compared 
to use of these antibiotics only after the occurrence of 
clinically overt skin changes. 
Perioperative prophylaxis in patients undergoing 
oncological surgery is also recommended. Prophylactic 
management in patients with higher risk of urinary tract 
infections, chronic skin lesions, ascites, or hepatic encepha-
lopathy should be individualised based on their current 
clinical situation, without any universal recommendations. 
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However, the side effects of prophylactic antibiotic 
treatment should not be underestimated, and their risk 
should not outweigh the potential benefits.
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